Biopharma News

Aug 24, 2018
By BioPharm International Editors
Dompé Farmaceutici’s Oxervate (cenegermin), a topical eye drop, is the first treatment approved by the agency for neurotrophic keratitis, a rare disease affecting the cornea.
Aug 17, 2018
By BioPharm International Editors
The acquisition is expected to support Emergent BioSolutions’ focus on public health threats and emerging infectious disease.
Aug 17, 2018
By BioPharm International Editors
The acquisition will strengthen Astellas Pharma’s position in ophthalmology.
Aug 16, 2018
By BioPharm International Editors
The companies entered a multi-year R&D collaboration to develop mRNA-based flu vaccines.
Aug 13, 2018
By BioPharm International Editors
The new drug, Onpattro (patisiran), by Alnylam Pharmaceuticals, is in a new class of drugs called small interfering ribonucleic acid (siRNA) treatment.
Aug 07, 2018
By BioPharm International Editors
The European Commission (EC) approved Pfizer’s Trazimera (trastuzumab), a biosimilar to Roche’s Herceptin, to treat certain breast and gastric cancers.
Aug 06, 2018
By BioPharm International Editors
Boehringer Ingelheim joins Oxford BioMedica, UK Cystic Fibrosis Gene Therapy Consortium, and Imperial Innovations to form a partnership for developing a new gene therapy to treat cystic fibrosis.
Aug 06, 2018
By BioPharm International Editors
The companies will collaborate on the discovery, development, and commercialization of cell therapies for cancer.
Aug 02, 2018
By BioPharm International Editors
The company broke ground on its $200-million, 120,000-sq-ft biomanufacturing plant in West Greenwich, RI.
Aug 02, 2018
By BioPharm International Editors
Stem-cell developer TiGenix has been acquired by Takeda Pharmaceutical for approximately EUR 520 million (US$604 million).
native1_300x100
lorem ipsum